IndustryCompany release

Shoulder Innovations lifts 2026 revenue outlook to $68-70M after 38% rise in third-quarter sales

🇺🇸 Shoulder Innovations, Inc. (SI) · Thu 05 Nov 2026

The shoulder-focused medtech company reported $16.2 million in Q3 net revenue and flagged a new 510(k) clearance, first InSet Go cases, a patent settlement and a distribution partnership.

Shoulder Innovations (NYSE: SI), a medtech company focused on shoulder arthroplasty, reported third-quarter 2026 results on 5 November 2026. Net revenue for the quarter was $16.2 million, which the company's headline describes as a 38% year-on-year increase.

Alongside the results, the company raised its full-year revenue guidance to a range of $68 million to $70 million.

On the regulatory and product side, the quarter included US Food and Drug Administration 510(k) clearance and launch of the N-22 humeral head, which is intended for patients with metal hypersensitivity. The company also performed the first cases with its InSet Go glenoid implant.

Shoulder Innovations also reported a settlement of patent litigation with Catalyst OrthoScience and a partnership with ALM Ortho. The material available to VigiEye did not include the terms of either arrangement, so their commercial or legal details are not known.

For context, a 510(k) clearance is the FDA pathway through which a device may be marketed on the basis of substantial equivalence to a legally marketed predicate device.

What it means for your team

  • The N-22 clearance shows a 510(k) route being used for a humeral head aimed at patients with metal hypersensitivity, a niche that regulatory teams in orthopaedics may wish to track.
  • First clinical use of InSet Go means early real-world performance and post-market surveillance data will begin to accumulate for the new glenoid implant.
  • The settlement with Catalyst OrthoScience removes one patent dispute from the company's litigation picture, though terms were not available in the source material.
  • Market-access teams should note the raised guidance of $68-70 million as a signal of demand in the shoulder arthroplasty segment.

Company's press release (SEC filing): Shoulder Innovations, Inc. ↗

Article written by VigiEye from the official source (Shoulder Innovations, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →